EUVIMEDEUVIMED entdecken
Vergleichsstudie

Endovascular therapy versus bypass for chronic limb-threatening ischemia in a real-world practice

Sina Zarrintan, Shima Rahgozar, Elsie G Ross, Alik Farber, Matthew T Menard, Michael S Conte, Mahmoud B Malas

Journal of Vascular Surgery · 2024-10 · 80 (4) · 1169-1181

DOI: 10.1016/j.jvs.2024.04.067 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Vascular Surgery, 2024-10. Verfasst von Sina Zarrintan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Vascular & Endovascular Surgery, University of California San Diego (UCSD), San Diego, CA. Hauptthemen laut MEDLINE: Endovascular Procedures, Amputation, Surgical, Limb Salvage, Peripheral Arterial Disease. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The recent Best Endovascular vs Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) study showed that bypass was superior to endovascular therapy (ET) in patients with chronic limb-threatening ischemia (CLTI) deemed suitable for either approach who had an available single-segment great saphenous vein (GSV). However, the superiority of bypass among those lacking GSV was not established. We aimed to examine comparative treatment outcomes from a real-world CLTI population using the Vascular Quality Initiative-Medicare-linked database. METHODS: We queried the Vascular Quality Initiative-Medicare-linked database for patients with CLTI who underwent first-time lower extremity revascularization (2010-2019). We performed two one-to-one propensity score matchings (PSMs): ET vs bypass with GSV (BWGSV) and ET vs bypass with a prosthetic graft (BWPG). The primary outcome was amputation-free survival. Secondary outcomes were freedom from amputation and overall survival (OS). RESULTS: Three cohorts were queried: BWGSV (N = 5279, 14.7%), BWPG (N = 2778, 7.7%), and ET (N = 27,977, 77.6%). PSM produced two sets of well-matched cohorts: 4705 pairs of ET vs BWGSV and 2583 pairs of ET vs BWPG. In the matched cohorts of ET vs BWGSV, ET was associated with greater hazards of death (hazard ratio [HR] = 1.34, 95% confidence interval [CI], 1.25-1.43; P < .001), amputation (HR = 1.30, 95% CI, 1.17-1.44; P < .001), and amputation/death (HR = 1.32, 95% CI, 1.24-1.40; P < .001) up to 4 years. In the matched cohorts of ET vs BWPG, ET was associated with greater hazards of death up to 2 years (HR = 1.11, 95% CI, 1.00-1.22; P = .042) but not amputation or amputation/death. CONCLUSIONS: In this real-world multi-institutional Medicare-linked PSM analysis, we found that BWGSV is superior to ET in terms of OS, freedom from amputation, and amputation-free survival up to 4 years. Moreover, BWPG was superior to ET in terms of OS up to 2 years. Our study confirms the superiority of BWGSV to ET as observed in the BEST-CLI trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endovascular ProceduresAmputation, SurgicalLimb SalvagePeripheral Arterial DiseaseChronic Limb-Threatening IschemiaDatabases, FactualHumansMaleFemaleAgedAged, 80 and overUnited StatesRetrospective StudiesTime FactorsRisk FactorsBlood Vessel Prosthesis ImplantationRisk AssessmentSaphenous VeinVascular GraftingMedicareTreatment OutcomeIschemia

Stichwörter der Autor:innen

BypassChronic limb-threatening ischemiaEndovascular therapyGraftGreat saphenous vein

Autor:innen und Institutionen

  • Department of Surgery, Division of Vascular & Endovascular Surgery, University of California San Diego (UCSD), San Diego, CA.
  • Department of Surgery, Division of Vascular & Endovascular Surgery, Boston University School of Medicine, Boston, MA.
  • Department of Surgery, Division of Vascular & Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Department of Surgery, Division of Vascular & Endovascular Surgery, University of California San Francisco (UCSF), San Francisco, CA.
  • Department of Surgery, Division of Vascular & Endovascular Surgery, University of California San Diego (UCSD), San Diego, CA. Electronic address: mmalas@health.ucsd.edu.

Zitieren

APA

Zarrintan, S., Rahgozar, S., Ross, E. G., Farber, A., Menard, M. T., Conte, M. S., & Malas, M. B. (2024). Endovascular therapy versus bypass for chronic limb-threatening ischemia in a real-world practice. Journal of Vascular Surgery, 80(4), 1169-1181. https://doi.org/10.1016/j.jvs.2024.04.067

Vancouver

Zarrintan S, Rahgozar S, Ross EG, Farber A, Menard MT, Conte MS, et al. Endovascular therapy versus bypass for chronic limb-threatening ischemia in a real-world practice. Journal of Vascular Surgery. 2024;80(4):1169-1181. doi:10.1016/j.jvs.2024.04.067

BibTeX
@article{Zarrintan2024,
  author = {Zarrintan, Sina and Rahgozar, Shima and Ross, Elsie G and Farber, Alik and Menard, Matthew T and Conte, Michael S and Malas, Mahmoud B},
  title = {Endovascular therapy versus bypass for chronic limb-threatening ischemia in a real-world practice},
  journal = {Journal of Vascular Surgery},
  year = {2024},
  volume = {80},
  number = {4},
  pages = {1169--1181},
  doi = {10.1016/j.jvs.2024.04.067}
}
Kostenlos starten →